BTI
RNTX

Blue Trust Inc’s Rein Therapeutics RNTX Stock Holding History

Blue Trust Inc’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21 Hold
20
– – ﹤0.01% 2436
2026
Q1 		$26 Hold
20
– – ﹤0.01% 2485
2025
Q4 		$23 Hold
20
– – ﹤0.01% 2524
2025
Q3 		$23 Hold
20
– – ﹤0.01% 2559
2025
Q2 		$28 Hold
20
– – ﹤0.01% 2434
2025
Q1 		$35 Buy
+20
New +$42 ﹤0.01% 2459

Other funds holding RNTX

SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
CPIG
Chicago Partners Investment Group Chicago, Illinois $5B AUM 26.84% 1-Year Est. Return
GG
Gleason Group Prospect, Kentucky $1.15B AUM 21.11% 1-Year Est. Return
JWA
JFS Wealth Advisors Hermitage, Pennsylvania $2.01B AUM 21.74% 1-Year Est. Return

Blue Trust Inc's RNTX Position: Q2 2026 in Review

Blue Trust Inc held its Rein Therapeutics (RNTX) position steady in Q2 2026 at 20 shares worth $21. The position accounts for ﹤0.01% of the portfolio, ranked #2436.

Blue Trust Inc first reported a position in RNTX in Q1 2025 and has held it in 6 quarters since. The position peaked at $35 in Q1 2025. 6 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

  • Blue Trust Inc held 20 shares of Rein Therapeutics worth $21 as of Q2 2026.
  • Blue Trust Inc left its Rein Therapeutics share count unchanged in Q2 2026.
  • Rein Therapeutics made up ﹤0.01% of Blue Trust Inc's portfolio in Q2 2026, its #2436 holding.
  • Blue Trust Inc first reported a position in Rein Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Blue Trust Inc's Rein Therapeutics position peaked at $35 in Q1 2025.
  • 6 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on Blue Trust Inc's 13F filing for Q2 2026, filed 21 Jul 2026.